Abstract
This study estimates the cost-effectiveness and budget impact of introducing ferric carboxymaltose (FCM) for the treatment of iron deficiency (ID) in patients with left ejection fraction (LVEF) <50%, stabilised after an episode of acute heart failure (AHF), from the perspective of healthcare payers in 5 European countries.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
